mRNA expression of GPRC5D in malignant cell lines

GPRC5D, a promising therapeutic target for multiple myeloma

In 2023…… On May 12th, LaNova announced that AstraZeneca will receive an exclusive global license for LM-305’s research, development, and commercialization. LM-305 is a new pre-clinical stage antibody-drug conjugate (ADC) targeting GPRC5D. LaNova Medicines will receive an immediate payment of $55 million and $545 million in additional development and commercial milestone payments. On May 19th, the clinical trial application for OriCAR-017 […]

Blog , 2023-07-14

TRPA1, what a therapeutic target for pain!

The transient receptor potential ankyrin 1 (TRPA1) is a non-selective cation channel that allows the passage of Ca2+, thereby increasing intracellular Ca2+ levels. TRPA1 has garnered significant attention due to its ability to respond to various environmental stimuli and its involvement in pain perception and inflammatory processes. As of now, there are approximately 22 drugs […]

Blog , 2023-07-05

Recombinant proteins for your cancer research and COVID studies!

News 2022-06-28